TY - JOUR
T1 - Antithrombotic therapy
T2 - Role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts)
AU - Fuster, V.
AU - Chesebro, J. H.
PY - 1981
Y1 - 1981
N2 - In this three-part series, the first part described the role of platelets in thrombogenesis, this second part considers the pharmacologic effects of platelet-inhibitor drugs, and the third part will discuss their clinical application. This second article comprises (1) the physiologic contribution of the vessel wall to the prevention of thrombosis, particularly the role of prostacyclin, (2) the mechanisms of action of platelet-inhibitor drugs in the prevention of thrombosis, (3) the ideal dose and ideal therapeutic combinations of conventional platelet-inhibitor drugs, (4) other agents and new agents that inhibit platelet function, and (5) drug side effects.
AB - In this three-part series, the first part described the role of platelets in thrombogenesis, this second part considers the pharmacologic effects of platelet-inhibitor drugs, and the third part will discuss their clinical application. This second article comprises (1) the physiologic contribution of the vessel wall to the prevention of thrombosis, particularly the role of prostacyclin, (2) the mechanisms of action of platelet-inhibitor drugs in the prevention of thrombosis, (3) the ideal dose and ideal therapeutic combinations of conventional platelet-inhibitor drugs, (4) other agents and new agents that inhibit platelet function, and (5) drug side effects.
UR - http://www.scopus.com/inward/record.url?scp=0019729704&partnerID=8YFLogxK
M3 - Article
C2 - 7010003
AN - SCOPUS:0019729704
SN - 0025-6196
VL - 56
SP - 185
EP - 195
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 3
ER -